Before you sell to, join or invest in Cardurion Pharmaceuticals, Inc.
MentionFox check on Cardurion Pharmaceuticals, Inc.: only 1 source on file so far (checked 10 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/cardurion-pharmaceuticals-inc-form-d-22000002
Check Cardurion Pharmaceuticals, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Cardurion Pharmaceuticals, Inc.?
Cardurion Pharmaceuticals, Inc. filed a Form D with the Securities and Exchange Commission on 2022-12-30.
Cardurion Pharmaceuticals, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 30, 2022. The filing reports $17.50M sold. Its industry group is Biotechnology. It names Peter Lawrence (Executive Officer, Director), Michael Mendelsohn (Executive Officer, Director), Kenneth Novack (Director) (SEC Form D, December 30, 2022).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Cardurion Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2022-12-30 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Cardurion Pharmaceuticals, Inc.
Free to see. No signup.
More on the people and the money behind Cardurion Pharmaceuticals, Inc., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in December 2022, largest first.
Get an email when Cardurion Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Cardurion Pharmaceuticals, Inc. raises, hires or launches. No email unless you switch it on.
Watch Cardurion Pharmaceuticals, Inc. →Get the full cited report on Cardurion Pharmaceuticals, Inc.
What the filing shows about Cardurion Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cardurion Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Cardurion Pharmaceuticals, Inc.'s address as 78 Blanchard Road, Suite 200, Burlington, MA 01803.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Cardurion Pharmaceuticals, Inc. See pricing
Cardurion Pharmaceuticals, Inc. is a registered filer with the SEC (CIK 1702453) and has filed since 2022-12-30. 3 filings are on record, the latest on 2024-07-24.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Cardurion Pharmaceuticals, Inc.'s Form D of 2022-12-30 names Peter Lawrence, Michael Mendelsohn, Kenneth Novack and 5 more as its officers, directors or promoters.
Its new offerings report $277.91M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 755 filings in Biotechnology, totalled by week.
Peter Lawrence is named as Executive Officer and Director on the Form D that Cardurion Pharmaceuticals, Inc. filed with the SEC on 30 December 2022, one of 8 people that filing names.
Michael Mendelsohn is named as Executive Officer and Director on the Form D that Cardurion Pharmaceuticals, Inc. filed with the SEC on 30 December 2022, one of 8 people that filing names.
Kenneth Novack is named as Director on the Form D that Cardurion Pharmaceuticals, Inc. filed with the SEC on 30 December 2022, one of 8 people that filing names.
Jeb Keiper is named as Director on the Form D that Cardurion Pharmaceuticals, Inc. filed with the SEC on 30 December 2022, one of 8 people that filing names.
Amy Schulman is named as Director on the Form D that Cardurion Pharmaceuticals, Inc. filed with the SEC on 30 December 2022, one of 8 people that filing names.
Nicholas Downing is named as Director on the Form D that Cardurion Pharmaceuticals, Inc. filed with the SEC on 30 December 2022, one of 8 people that filing names.
Keith Gottesdiener is named as Director on the Form D that Cardurion Pharmaceuticals, Inc. filed with the SEC on 30 December 2022, one of 8 people that filing names.
Adam Koppel is named as Director on the Form D that Cardurion Pharmaceuticals, Inc. filed with the SEC on 30 December 2022, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2022-12-30 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Cardurion Pharmaceuticals, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cardurion Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cardurion Pharmaceuticals, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cardurion Pharmaceuticals, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Cardurion Pharmaceuticals, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Cardurion Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/cardurion-pharmaceuticals-inc-form-d-22000002